RTW committed $100M in U.S. launch funding, subject to U.S. Food and Drug Administration (FDA) approval of aglatimagene besadenovec (aglatimagene ...

As Candel Therapeutics gears up for a planned U.S. approval push for its prostate cancer drug later this year, RTW ...

The $100 million equity raise is expected to fund commercialization preparations for CAN-2409 in early-stage, localized ...

Enolen's fast track designation by the FDA aims to expedite its development for localized prostate cancer treatment, addressing unmet medical needs. The localized delivery technology targets ...

The phase 2 ProFocal Laser Therapy for Prostate Tissue Ablation (PFLT-PC) trial tested a cooled laser focal therapy device for intermediate-risk prostate cancer treatment.

Doctors say active monitoring, hormone therapy and newer focal treatments are reshaping care decisions for men.

People with localized prostate cancer treated according to guidelines developed by an international panel of doctors are more likely to die of something other than the disease, new research shows. A ...

Development and Validation of an Adapted Tool to Measure Health-Related Social Needs for the Prostate Cancer Population in Nigeria This study included 110 patients with a median age of 67 years. Most ...

Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that ...